Emyria (ASX:EMD) has positioned itself at the centre of a rapidly evolving global mental health landscape, launching a new services platform designed to support international drug sponsors as demand accelerates for next-generation therapies.
The initiative marks a significant shift for the company, introducing a dual revenue model that combines its established treatment programs with a new stream of sponsor-funded services built on its existing clinical infrastructure.
The move comes at a time when more than 50 psychedelic-assisted therapy programs are advancing through clinical development worldwide, targeting conditions such as PTSD and treatment-resistant depression. Unlike conventional pharmaceuticals, these therapies require intensive psychotherapy, extended treatment sessions, specialised facilities and highly trained multidisciplinary teams.
Emyria has spent several years building what it describes as a rare and difficult-to-replicate network of clinics, practitioners, and governance systems capable of meeting those demands. Through its Empax network, the company offers structured treatment programs, national referral pathways, and a workforce of around 100 therapists and specialist psychiatrists, supported by purpose-built clinical environments and established regulatory processes. It has also developed systems to capture longitudinal patient data, with results indicating durable remission outcomes in treatment-resistant PTSD extending beyond 12 months.
This foundation now underpins the newly launched global partnership program, which allows international drug sponsors and research organisations to access Emyria’s infrastructure for both clinical trials and eventual commercial rollout. By leveraging an already operational platform, sponsors can reduce execution risk and accelerate deployment timelines, while Emyria generates high-margin revenue without significant additional capital investment.
The model is already in practice. Emyria is working with North American-based Psyence Group as a clinical trials site for a Phase IIb study involving patients with advanced cancer, demonstrating that its systems are compliant and trusted by international partners. The broader program formalises this capability and opens it to a wider pool of sponsors, with the company reporting growing inbound interest from global research organisations.
Emyria Executive Chair Greg Hutchinson underscored the scarcity of the company’s capabilities, stating, “The experience and infrastructure required to safely deliver these therapies in complex patient populations is scarce and highly valuable. Emyria has spent years building this capability.”
He added, “The Empax Global Partnership Program makes that capability available to international drug sponsors developing the next generation of mental health treatments. We are already delivering for Psyence Group and are seeing positive inbound interest from sponsors and CROs seeking scalable, compliant clinical delivery solutions.”